BMS will showcase nearly 60 disclosures at ESMO 2026 (Oct 23-27, Madrid), including late-breaking Phase 3 data for iza-bren in NSCLC and breast cancer, Phase 2 pumitamig data in NSCLC, and long-term survival for Opdivo+Yervoy.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
